Publications by authors named "A M Kamphuis"
Treatment options for children living with HIV have historically been less effective, less practical and more difficult to implement compared with those for adults, as the research and development of new drugs for children has lagged behind. Significant progress has been achieved in response to the paediatric HIV epidemic over the last decade. Several optimised paediatric antiretroviral formulations are currently available or in development, including fixed-dose combination tablets containing a complete World Health Organization-recommended regimen.
View Article and Find Full Text PDFArticle Synopsis
- The UNIVERSAL project aims to develop a fixed-dose combination of paediatric dolutegravir (DTG), emtricitabine (FTC), and tenofovir alafenamide (TAF) to improve dosing for children.
- A study on 15 healthy volunteers tested the pharmacokinetics (PK) of these medications combined in various doses, assessing blood concentration differences over 48 hours.
- Results indicated no significant PK interactions with DTG, FTC, and tenofovir (TFV), although TAF showed variability, leading to a conclusion that the formulations are safe for use without clinically relevant interactions.
Article Synopsis
- The introduction of BRAF/MEK inhibition and immune checkpoint inhibitors (ICI) has led to significantly better outcomes for patients with advanced melanoma.
- A study analyzed data from the Dutch Melanoma Treatment Registry to explore the connection between the time to first distant recurrence (TFDR) and patient survival after systemic therapy.
- Results showed that patients with longer TFDR experienced better progression-free survival (PFS) and overall survival (OS), regardless of whether they received ICI or targeted therapy, with notable differences in survival times for those with TFDR less than 2 years versus more than 5 years.
Importance: Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy.
Objective: To determine the association of toxic effect management with progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy.